IL4 and asthma: Dupilumab, a monoclonal antibody targeting IL4/IL13 receptor, has demonstrated its efficacy since 2018 in improving asthma control, lung function, and reducing asthma exacerbation and OCS-dependence in asthmatics with type 2 inflammation [4].